Saturday, April 2, 2011

March of Dimes Update

It looks like the March of Dimes took a closer look at that whole inexcusable increase in the price of progesterone shots. Just yesterday they finally had something to say about it on their website:

MOD responds to Ther-Rx

In the past few weeks, there has been a torrent of concern over the availability of progesterone therapy for women hoping to prevent premature birth.  We have held discussions with physician groups, various organizations and the manufacturer of the drug.  Ther-Rx Corporation’s handling of the launch of Makena, and the initial list price, were extremely disappointing and unacceptable to the March of Dimes and the families we represent.  While Ther-Rx Corporation’s decision yesterday to reduce the list price of Makena to $690 and to expand patient financial assistance are steps in the right direction toward making an FDA-approved progesterone therapy product more widely available, it’s not enough.  The March of Dimes has decided to exercise our right to terminate our current contract and sever all professional relationships with Ther-Rx.

The March of Dimes will continue to explore all options for ensuring access to progesterone therapy for all medically eligible women. Access for women to treatment to prevent premature birth is and always has been our paramount concern. We hope that the controversy surrounding Makena has helped raise awareness that progesterone therapy is a safe and effective treatment for prevention of preterm birth and that more obstetricians will consider it for appropriate patients.

I'm glad they finally spoke up. I'm glad Ther-Rx halved the price of the shots. It hasn't taken away my anger and frustration (there's no one like the newly awakened for taking umbrage), but at least both groups responded to a clearly outrageous situation. It isn't good enough, but it's a start.


kiddoh said...

Tia, did you see the FDA news? From the American College of Obstetrics and Gynecology:
On March 30, the FDA announced that it "does not intend to take enforcement action against pharmacies that compound hydroxyprogesterone caproate," countering Ther-Rx's previous assertion, insisting that compounding pharmacies "cease and desist" any further compounding of 17p. This announcement gives a green light to the many pharmacies that ob-gyns have relied on for many years to continue compounding hydroxyprogesterone caproate, and helps ensure a steady supply of this low cost drug. The FDA notes that it reserves the right to bring enforcement action against compounding pharmacies that produce inferior or unsafe formulations.

MOD, ACOG, and the FDA are doing right by women, even if Ther-Rx isn't.


tia said...

Stephanie, thanks so much! It is a relief to read that the FDA isn't going to let Ther-Rx screw over so many people. I really appreciate your sharing this. Whew.

AG Ambroult said...

huh. iiiiiinteresting.
thanks for the update.